Please assess the completion status of the following clinical trial:

Trial Title: Metabolic Signatures and Biomarkers in Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-60 years~* Diagnosis of schizophrenia~* Actively psychotic~* No more than a single dose of antipsychotic in the preceding 2 weeks~Exclusion Criteria:~* Mental retardation, epilepsy or history of head trauma~* Substance use disorder that explains the majority of the psychopathology~* Pregnant or lactating females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Aripiprazole for 4 weeks (Type: ACTIVE_COMPARATOR): Blood is drawn for baseline. 20 Subjects are randomly assigned to receive Aripiprazole for weeks weeks with a starting dose of 10mg/day and the dose will be titrated to a maximum of 30mg /day based on effectiveness and tolerability. After 4 weeks of treatment, blood will be drawn again for metabolomics.
- Risperidone for 4 weeks (Type: ACTIVE_COMPARATOR): Blood will be drawn for baseline evaluation. 20 Subjects will be randomly assigned to receive risperidone at a starting dose of 2mg/day, and can be increased to 6mg/day based on response of the subject. After 4 weeks of medication, blood is drawn again.
- Healthy volunteers (Type: OTHER): Fasting blood samples will be drawn from healthy volunteers to match age, race and gender with the research subjects for comparison.

Based on this trial design, predict the completion outcome and termination type (if applicable).